COO Jeffrey Millard Exits Ensysce Biosciences During Strategic Review and Cash Crunch
ENSC sits 27% above its 52-week low of $0.23 on light trading volume (0.2× avg).
Summary
Ensysce Biosciences announced that COO Jeffrey Millard resigned effective July 10, 2026. The departure hits as the company confronts a cash crisis, a going-concern warning, and an ongoing strategic review.
Key Events · Executive and Board Changes · ENSC
-
COO Resigns Effective Immediately
On July 10, 2026, Chief Operating Officer Jeffrey Millard resigned with no reason given and no successor announced. The departure is immediate, creating a leadership void.
-
Financial Distress Backdrop
The resignation comes on the heels of a going-concern warning, a sharply wider Q1 net loss, and a formal strategic alternatives review launched in May 2026.
-
Nasdaq Delisting Risk
Adding to the uncertainty, a second Nasdaq delisting notice arrived in May 2026 after the company failed to satisfy the $2.5 million stockholders' equity requirement.
-
No Successor Named
The filing makes no mention of an interim or permanent replacement for the COO role, leaving operational oversight unclear during a period of extreme stress.
Analysis · ENSC · Life Sciences
The abrupt exit of the Chief Operating Officer strips away a key operational leader at a moment when the company can least afford it. Already grappling with a going-concern warning, a formal review of strategic alternatives, and a Nasdaq delisting notice for insufficient equity, the loss of the COO now casts doubt on internal stability and the capacity to execute any turnaround or transaction. The resignation takes effect immediately, with no successor named, leaving day-to-day leadership in limbo.
At the time of this filing, ENSC was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.